Repligen Shares Purchased by Geneva Capital Management

Institutional investor increases stake in biotech company Repligen Corporation

Mar. 11, 2026 at 11:40am

Got story updates? Submit your updates here. ›

Geneva Capital Management LLC, a major institutional investor, has increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 22.4% in the third quarter. The fund now owns approximately 596,768 shares, or 1.06% of the biotechnology company's stock, making it one of Repligen's largest shareholders.

Why it matters

Repligen is a leading manufacturer of critical bioproduction consumables used in the development and manufacturing of biopharmaceuticals. As a key supplier to the growing biotech industry, increased institutional investment in the company signals confidence in its growth prospects and the overall strength of the biopharmaceutical market.

The details

According to a recent SEC filing, Geneva Capital Management purchased an additional 109,234 shares of Repligen in the third quarter, bringing its total stake in the company to 596,768 shares. This represents approximately 1.06% of Repligen's outstanding shares and makes Geneva Capital one of the company's 23rd largest shareholders.

  • Geneva Capital Management increased its Repligen holdings in the third quarter of 2026.

The players

Geneva Capital Management LLC

A major institutional investment firm that has increased its stake in Repligen Corporation, a leading manufacturer of critical bioproduction consumables.

Repligen Corporation

A biotechnology company that develops and manufactures high-value consumable products for bioprocessing applications, including chromatography resins, filtration membranes, and single-use technologies.

Got photos? Submit your photos here. ›

The takeaway

The increased investment from Geneva Capital Management in Repligen highlights the growing importance of the biotech industry and the demand for specialized bioproduction equipment and consumables. As a key supplier to this market, Repligen's strong position and continued growth potential make it an attractive investment for institutional investors.